Dyslipidemia Archives - Endocrinology Advisor

The Lipid Paradox and CVD Risk in Rheumatoid Arthritis

By

October 16, 2020

Mechanistic and outcomes studies are warranted to elucidate the lipid paradox and CVD risk in rheumatoid arthritis (RA).

Thyroid

HDL Cholesterol Efflux May Be Impaired in Severe Short-Term Hypothyroidism

By

Amit Akirov, MD

September 15, 2020

High-density lipoprotein cholesterol efflux capacity may be impaired in patients with severe short-term hypothyroidism.

Cardiovascular and Metabolic Disorders

Evolocumab Reduces LDL-C in Pediatric Heterozygous FH

By

Brian Park, PharmD

September 8, 2020

The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.

Cardiovascular and Metabolic Disorders

Metabolic Syndrome Linked to Worse Outcomes in COVID-19

September 8, 2020

Metabolic syndrome (MetS) is associated with a lethal outcome for patients with COVID-19.

Cardiovascular and Metabolic Disorders

Consistent LDL-C Lowering Reported With Twice-Yearly Inclisiran

By

Brian Park, PharmD

September 3, 2020

The post-hoc analysis included 2 placebo-controlled phase 3 studies (ORION-10 and -11) that evaluated the efficacy and safety of inclisiran sodium in more than 2300 adult patients.

Individuals on PrEP who become infected with HIV, such as those with poor adherence to treatment, may have delayed seroconversion on blood-based and oral-fluid-based rapid antibody tests.2 In one study, oral antibody reactivity was first observed a median of 125 days (range, 14-547 days) after HIV RNA or antibodies were observed in the blood.13 In another study, individuals who received PrEP were 3.49 times more likely than those on placebo to experience a delay of >100 days in detecting the infection.14 Based on these and other findings in the literature, it has been suggested that laboratory-based serum or plasma HIV tests should be used whenever possible to monitor individuals on PrEP.2 Additionally, in the setting of known or suspected poor PrEP adherence, the threshold for augmenting p24/IgM/IgG assays with NAT should be lowered.2

Cardiovascular and Metabolic Disorders

Higher Plasma Lp(a), Family History of CHD an Additive CVD Risk Factor

By

Colby Stong

September 1, 2020

Elevated plasma levels of lipoprotein(a) and family history of coronary heart disease (CHD) were found to be associated with a risk for cardiovascular disease.

Cardiovascular and Metabolic Disorders

Assessing the Prevalence and Treatment of Severe Hypercholesterolemia

By

Madeline Morr

August 25, 2020

Researchers used electronic health records to further understand the clinical features and gaps in treatment approaches for patients with severe hypercholesterolemia.

Cardiovascular and Metabolic Disorders

Pitavastatin Effectively Lowers Lipids in Dose-Dependent Fashion

August 20, 2020

Pitavastatin lowers blood total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides in a dose-dependent manner.

Cardiovascular and Metabolic Disorders

Priority Review Granted to Evinacumab for Homozygous FH

By

Brian Park, PharmD

August 14, 2020

Evinacumab is an investigational fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3).

Cardiovascular and Metabolic Disorders

Dyslipidemia Medication as Thrombosis Prophylaxis in Patients With COVID-19 and FH

By

Brandon May

August 11, 2020

The treatment of patients with familial hypercholesterolemia and COVID-19 with dyslipidemia medications may prevent the occurrence of thrombotic events.